Sam Brusco, Associate Editor07.21.23
BioSig, a company focused on intracardiac signal visualization, announced its BioSig AI Sciences (BAIS) subsidiary was chosen to join NVIDIA Inception, a program that partners with companies revolutionizing industries with advancements in artificial intelligence (AI) and data sciences.
NVIDIA Inception assists emerging-growth firms during critical stages of product development, prototyping, and deployment. Partners receive engineering guidance, technical training, hardware and software support, co-marketing, and exposure to the NVIDIA investment community.
BAIS will draw on NVIDIA’s resources as it advances research and development of its AI medical device platform, including developer application frameworks and domain-specific AI computing to build medical devices.
“We are thrilled to join an elite group of AI-centric technology companies leading the evolution of machine learning and AI across industries,” Ken Londoner, chairman, CEO, and founder of BioSig told the press. “We believe NVIDIA Inception will help advance BioSig’s role in identifying transformational applications of AI opportunities in healthcare.”
BAIS is training its AI platform with electrocardiogram (ECG) and intracardiac electrogram data from its PURE EP platform, which according to the company has been used in over 3,500 procedures to date.
The tech could help healthcare systems deploy a branded ChatGPT-like, multi-modal foundation model that understands structured, semi-structured, and unstructured medical data across time-series, text, image, video, and other clinically relevant signal modalities.
NVIDIA Inception assists emerging-growth firms during critical stages of product development, prototyping, and deployment. Partners receive engineering guidance, technical training, hardware and software support, co-marketing, and exposure to the NVIDIA investment community.
BAIS will draw on NVIDIA’s resources as it advances research and development of its AI medical device platform, including developer application frameworks and domain-specific AI computing to build medical devices.
“We are thrilled to join an elite group of AI-centric technology companies leading the evolution of machine learning and AI across industries,” Ken Londoner, chairman, CEO, and founder of BioSig told the press. “We believe NVIDIA Inception will help advance BioSig’s role in identifying transformational applications of AI opportunities in healthcare.”
BAIS is training its AI platform with electrocardiogram (ECG) and intracardiac electrogram data from its PURE EP platform, which according to the company has been used in over 3,500 procedures to date.
The tech could help healthcare systems deploy a branded ChatGPT-like, multi-modal foundation model that understands structured, semi-structured, and unstructured medical data across time-series, text, image, video, and other clinically relevant signal modalities.